153 related articles for article (PubMed ID: 16499078)
1. [9-nitrocamptothecin nanostructured lipid carrier system: in vitro releasing characteristics, uptake by cells, and tissue distribution in vivo].
Li JC; Sha XY; Zhang LJ; Fang XL
Yao Xue Xue Bao; 2005 Nov; 40(11):970-5. PubMed ID: 16499078
[TBL] [Abstract][Full Text] [Related]
2. [Preparation of PEG-modified nanostructured lipid carriers loaded with hydroxycamptothecin and tissue distribution in mice].
Zhang XX; Gan Y; Yang XG; Zhu CL; Gan L; Nie SF; Pan WS
Yao Xue Xue Bao; 2008 Jan; 43(1):91-6. PubMed ID: 18357740
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes.
Zhang LJ; Xing B; Wu J; Xu B; Fang XL
Pulm Pharmacol Ther; 2008; 21(1):239-46. PubMed ID: 17561423
[TBL] [Abstract][Full Text] [Related]
4. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying.
Zhang X; Pan W; Gan L; Zhu C; Gan Y; Nie S
Chem Pharm Bull (Tokyo); 2008 Dec; 56(12):1645-50. PubMed ID: 19043233
[TBL] [Abstract][Full Text] [Related]
5. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
[TBL] [Abstract][Full Text] [Related]
6. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation.
Liu X; Zhang Z; Jiang Y; Hu Y; Wang Z; Liu J; Feng R; Zhang J; Huang G
Drug Deliv; 2015 Feb; 22(2):223-9. PubMed ID: 24559497
[TBL] [Abstract][Full Text] [Related]
7. Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles.
Huang M; Wu W; Qian J; Wan DJ; Wei XL; Zhu JH
Acta Pharmacol Sin; 2005 Dec; 26(12):1512-8. PubMed ID: 16297352
[TBL] [Abstract][Full Text] [Related]
8. Soluplus(®) based 9-nitrocamptothecin solid dispersion for peroral administration: preparation, characterization, in vitro and in vivo evaluation.
Lian X; Dong J; Zhang J; Teng Y; Lin Q; Fu Y; Gong T
Int J Pharm; 2014 Dec; 477(1-2):399-407. PubMed ID: 25445521
[TBL] [Abstract][Full Text] [Related]
9. Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats.
Zhang S; Wang J; Pan J
Drug Deliv; 2016 Nov; 23(9):3696-3703. PubMed ID: 27749105
[TBL] [Abstract][Full Text] [Related]
10. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
11. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
Su Z; Shi Y; Xiao Y; Sun M; Ping Q; Zong L; Li S; Niu J; Huang A; You W; Chen Y; Chen X; Fei J; Tian J
Int J Pharm; 2013 Apr; 447(1-2):281-92. PubMed ID: 23396258
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers.
Jia L; Shen J; Zhang D; Duan C; Liu G; Zheng D; Tian X; Liu Y; Zhang Q
Int J Biol Macromol; 2012 Apr; 50(3):523-9. PubMed ID: 22301003
[TBL] [Abstract][Full Text] [Related]
13. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution.
Shen J; Deng Y; Jin X; Ping Q; Su Z; Li L
Int J Pharm; 2010 Dec; 402(1-2):248-53. PubMed ID: 20934499
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers.
Liu K; Sun J; Wang Y; He Y; Gao K; He Z
Drug Dev Ind Pharm; 2008 May; 34(5):465-71. PubMed ID: 18473227
[TBL] [Abstract][Full Text] [Related]
15. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity.
Shi B; Fang C; Pei Y
J Pharm Sci; 2006 Sep; 95(9):1873-87. PubMed ID: 16795003
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification.
Yuan H; Wang LL; Du YZ; You J; Hu FQ; Zeng S
Colloids Surf B Biointerfaces; 2007 Nov; 60(2):174-9. PubMed ID: 17656075
[TBL] [Abstract][Full Text] [Related]
17. 9-nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats.
Dadashzadeh S; Derakhshandeh K; Shirazi FH
Anticancer Drugs; 2008 Sep; 19(8):805-11. PubMed ID: 18690092
[TBL] [Abstract][Full Text] [Related]
18. Construction and in vitro/in vivo evaluation of 17-allylamino-17-demethoxygeldanamycin (17AAG)-loaded PEGylated nanostructured lipid carriers.
Wang Z; Wang J; Yang S; Hou S
Drug Dev Ind Pharm; 2016 Jan; 42(1):91-98. PubMed ID: 25853294
[TBL] [Abstract][Full Text] [Related]
19. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics.
Derakhshandeh K; Erfan M; Dadashzadeh S
Eur J Pharm Biopharm; 2007 Apr; 66(1):34-41. PubMed ID: 17070678
[TBL] [Abstract][Full Text] [Related]
20. Design and characterization of Amoitone B-loaded nanostructured lipid carriers for controlled drug release.
Luan J; Zhang D; Hao L; Li C; Qi L; Guo H; Liu X; Zhang Q
Drug Deliv; 2013 Nov; 20(8):324-30. PubMed ID: 24032657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
